Discontinued — last reported Q3 '23
Biogen Long-Term Debt - Fair Value decreased by 1.9% to $5.57B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.8%, from $5.47B to $5.57B. Over 5 years (FY 2020 to FY 2025), Long-Term Debt - Fair Value shows a downward trend with a -7.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A fair value lower than the carrying amount often indicates rising market interest rates or a change in credit risk.
The estimated market value of the company's long-term debt obligations if they were to be traded or settled in the curre...
Required disclosure that helps investors assess the sensitivity of debt to interest rate changes.
long_term_debt_fair_value| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.14B | $8.05B | $8.00B | $7.20B | $6.55B | $5.30B | $5.41B | $5.64B | $5.53B | $5.20B | $6.29B | $5.78B | $5.45B | $5.68B | $5.44B | $5.47B | $5.55B | $5.66B | $5.68B | $5.57B |
| QoQ Change | — | -1.2% | -0.5% | -10.1% | -9.0% | -19.1% | +2.1% | +4.3% | -1.9% | -6.1% | +21.0% | -8.0% | -5.8% | +4.3% | -4.3% | +0.6% | +1.5% | +2.0% | +0.3% | -1.9% |
| YoY Change | — | — | — | — | -19.6% | -34.2% | -32.4% | -21.6% | -15.5% | -1.8% | +16.2% | +2.5% | -1.5% | +9.3% | -13.5% | -5.4% | +1.9% | -0.4% | +4.4% | +1.8% |